By Robert Honeywill: There was much excitement about Novartis' acute heart failure drug Serelaxin, when study results were first posted in late 2012. But in April this year, an FDA Committee unanimously rejected approval. In retrospect,...Show More Summary
By Kanak Kanti De: Swiss drug maker Novartis AG (NYSE:NVS) recently reported strong data from the PARADIGM-HF trial of its new heart failure medicine LCZ696. The company's investigational heart failure medicine was found to be superior to ACE-inhibitor enalapril on key endpoints. Show More Summary
Kevin Bond’s 2 month old son, Hudson, is battling a very serious health condition called cardiomyopathy. The rare condition is a disease of the heart muscles, which could lead to heart failure if not carefully monitored. In an attempt...Show More Summary
Researchers say over an hour of moderate – or half an hour of vigorous exercise – per day may lower your risk of heart failure by 46 percent, according to a new study reported in the American Heart Association journal Circulation: Heart Failure. Heart failure is a common, disabling disease that accounts for about 2 […]
People with diabetes who appear otherwise healthy may have a six-fold higher risk of developing heart failure regardless of their cholesterol levels, new Johns Hopkins Bloomberg School of Public Health research suggests.
As a heart fails, losing its ability to squeeze blood through the circulatory system, the body releases a neurohormone that interferes with the heart's best chance to improve contractility, a team of Temple University School of Medicine researchers show in a study published September 9th in the American Heart Association journal, Circulation. read more
By Chronic Bull: Novartis AG (NYSE:NVS) brings good news for chronic heart failure patients as the company's experimental drug has shown remarkable efficacy in prolonging the lives of people suffering from the disease. The drug, LCZ696,...Show More Summary
By Investing Doc: As a primary care physician, I don't often have the opportunity to use "blockbuster" drugs. This is often because, as a primary care physician, if you're treating somebody with the newest molecular thingamabob because they're that sick, then you're doing it wrong. Show More Summary
We frequently discuss how commercial sponsors manipulate clinical research to serve their interests. There have been many cases of commercially sponsored controlled trials ostensibly designed to assess their sponsors' products manipulated to make these products look better.Unfortunately, often such manipulation seems to escape public notice. Show More Summary
By Robert Honeywill: This is an update to my article, "Sunshine Heart C-Pulse: A Paradigm Shift In Heart Failure Therapy". It is provided to both inform and to facilitate discussion on two new matters of considerable interest arising soon after release of that article. Show More Summary
Highlight Among patients with chronic kidney disease, the risks of developing kidney failure or dying prematurely increased markedly in a step-wise fashion after each successive hospitalization for heart failure.
Summer must be over, because the next new blockbuster drug appears to be here. At the end of August, the media heralded the results of a study of a new product for congestive heart failure (CHF) from Novartis.Novartis' New "Game Changer"...Show More Summary
By AtonRa Partners: Heart failure: still 15% upside on long-term EPS expectations Heart failure drug LCZ696 was expected to be a major catalyst. It clearly delivered on expectations last week this week when Novartis (NYSE:NVS) unveiled details of phase III results. Show More Summary
The expected result emerges from the study results noted below, joining the mountain of evidence linking exercise and long term health. In human studies it is challenging to prove causation, but the evidence for regular moderate exercise...Show More Summary
Ginger Taylor wrote this editorial for the Portland (Maine) Press Herald. Maine Voices: Breakdown in accountability at heart of decline in vaccinations Opposition to the current U.S. vaccination program is based on its failures, denial and bad law and policy....
Being physically active every day may lower your risk of developing heart failure. The more active you are, the greater your protection from heart failure, studies show.
Novartis LCZ696 may give doctors the first significant high blood pressure drug approved in decades if regulators give it the okay next year.
In a new study reported in the American Heart Association journal Circulation: Heart Failure, researchers say more than an hour of moderate or half an hour of vigorous exercise per day may lower your risk of heart failure by 46 percent. Heart...Show More Summary
Boston Scientific's stimulator showed no benefit in big European trial, but Cyberonics' smaller, earlier-stage trial succeeded
Experts have sounded a call to action for policy makers at local, national, and international levels to promote heart failure prevention, improve heart failure awareness among healthcare professionals, ensure equity of care for all patients with heart failure, support and empower patients and their caregivers, and promote heart failure research. read more